Abstract |
Sequential hemibody irradiation (SHB) was integrated with combination chemotherapy and local irradiation (LRT) in the induction and consolidation phases of a therapeutic protocol for small cell lung carcinoma (SCLC). Forty-one previously untreated patients were entered into this program. Among 38 evaluable patients (20 with limited disease [LD] and 18 with extensive disease [ED], the overall response rate was 63% (90% in LD and 33% in ED patients). The estimated overall survival is 8.1 months. The major toxicity has been myelosuppression--especially thrombocytopenia. The frequency of previously described " acute radiation syndromes" and radiation pneumonitis associated with hemibody irradiation have been substantially decreased at the current dosage with premedication and shielding techniques. The integration of SHB as a systemic therapy with combination chemotherapy and LRT is a feasible program for sequential administration of non-cross-resistant agents in SCLC and may be beneficial in patients with limited disease.
|
Authors | B L Powell, D V Jackson Jr, C W Scarantino, E Pope, R Choplin, J B Craig, J N Atkins, M R Cooper, J O Hopkins, R McMahan |
Journal | International journal of radiation oncology, biology, physics
(Int J Radiat Oncol Biol Phys)
Vol. 11
Issue 3
Pg. 457-62
(Mar 1985)
ISSN: 0360-3016 [Print] United States |
PMID | 2982771
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Vincristine
- Doxorubicin
- Cyclophosphamide
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carcinoma, Small Cell
(drug therapy, radiotherapy)
- Combined Modality Therapy
- Cyclophosphamide
(administration & dosage)
- Doxorubicin
(administration & dosage)
- Female
- Humans
- Lung Neoplasms
(drug therapy, radiotherapy)
- Male
- Middle Aged
- Vincristine
(administration & dosage)
- Whole-Body Irradiation
|